In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples;Klinik örneklerden izole edilen Candida glabrata suşlarιnιn amfoterisin B, flukonazol ve itrakonazole in vitro duyarlιlιǧιnιn araştιrιlmasι

Mikrobiyoloji Bulteni

Volumn 41, Issue 2, 2007, Pages 235-244

  Avcilar, Hüseyin ^a   Sancak, Banu ^a   Arikan, Sevtap ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Amphotericin B; Candida glabrata; Fluconazole; In vitro susceptibility; Itraconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; DOSE RESPONSE; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 38549181290     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-8.
2. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004; 53: 283-9.
3. Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003; 52: 71-7.
4. Pappas PG, Rex JH, Lee J, et al; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
5. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C.albicans. Clin Microbiol Rev 1999; 12: 80-96.
6. Segal E, Elad D. Candida species and Blastoschizomyces capitatus, pp: 423-60. Collier L, Ballows A, Susman M (eds), Topley and Wilson's Microbiology and Microbial Infections. 1998, 9th ed. Oxford University Press, New York.
7. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30: 19-24.
8. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
9. Koç AN, Kocagöz S, Erdem F, Gündüz Z. Outbreak of nosocomial fungemia caused by Candida glabrata. Mycoses 2002; 45: 470-5.
10. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-26.
11. Sims CR, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol 2006; 44: 2105-8.
12. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
13. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
14. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44: 1740-3.
15. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44: 529-35.
16. Larone DH. Medically Important Fungi. A Guide to Identification. 1995, 3rd ed. ASM Press, Washington, DC.
17. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A2. 2002, 2nd ed. NCCLS, Wayne, Pa.
18. Safdar A, Chatuvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001; 45: 2129-33.
19. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
20. Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22: 24-8.
21. Ghannoum MA. Susceptibility testing of fungi and correlation with clinical outcome. J Chemother 1997; 9 (Suppl 1): 19-24.
22. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-47.
23. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-54.
24. Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999; 43: 1289-90.
25. Peyron F, Favel A, Michel-Nguyen A, Gilly M, Regli P, Bolmstrom A. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol 2001; 39: 339-42.
26. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006; 50: 1287-92.
27. Yücesoy M, Karaman M. Candida türlerinin biyofilm üretimi ve antifungal duyarlilik paternleri. Mikrobiyol Bült 2004; 38: 91-98.
28. Safdar A, Chatuvedi M, Koll BS, Larone DH, Perlin DS, Armtrong D. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob Agents Chemother 2002; 46: 3268-72.
29. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-6.
30. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46: 1723-7.
31. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol 2003; 41: 1875-80.
32. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol 2003; 41: 2176-9.
33. Baddley JW, Smith AM, Moser SA, Pappas PG. Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital. Diagn Microbiol Infect Dis 2001; 39: 199-201.
34. Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol 2005; 20: 349-53.
35. Kaya D, Kaptanoǧlu S, Üstüner Z, Ertör O. Nötropenik hasta örneklerinden izole edilen mayalarin tiplendirilmesi ve flukonazole karşi direncin araştirilmasi. Klimik Derg 2001; 14: 14-6.
36. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129-34.